Joshua J. Meeks, MD, PhD

“It's going to be an important time for US urologists to identify that this is becoming the standard of care," says Joshua J. Meeks, MD, PhD.

"There really wasn't a difference in in surgical outcomes. The patients tolerated it very well,” says Joshua J. Meeks, MD, PhD.

“The NIAGARA approval really begins to bring immunotherapy into the neoadjuvant setting," says Joshua J. Meeks, MD, PhD.